Department of Hematology, AP-HP, Université de Paris, Paris, France.
Center for Cellular Immunotherapies and Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.
J Hematol Oncol. 2021 Nov 22;14(1):199. doi: 10.1186/s13045-021-01209-9.
Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This immune evasion may be due to CAR T cells dysfunction, a hostile tumor microenvironment, or resistant cancer cells. Here, we review the intrinsic resistance mechanisms of cancer cells to CAR T cell therapy and potential strategies to circumvent them.
尽管嵌合抗原受体 T 细胞在化疗耐药性血液恶性肿瘤患者中显示出显著的疗效，但仍有很大一部分患者抵抗或复发。这种免疫逃逸可能是由于 CAR T 细胞功能障碍、肿瘤微环境恶劣或耐药癌细胞所致。在此，我们综述了癌细胞对 CAR T 细胞治疗的内在抵抗机制，以及潜在的规避策略。
